- Generic name
- Tofacitinib
- Strength
- 5 mg
- Dosage form
- Tablet
- Manufactured by
- Renata PLC.
Jakrif-5 Tablet
About Jakrif-5 Tablet
Jakrif-5 is a 5 mg tablet containing tofacitinib, an immunosuppressant used for certain inflammatory conditions. It is prescribed for adults with rheumatoid arthritis who have not responded well to methotrexate.
There are 13 brands of Tofacitinib listed in Bangladesh. The lowest listed price is Tofacit 5 mg Tablet at ৳ 30.00 per unit.
What is Jakrif-5 Tablet?
Jakrif-5 is a tablet made by Renata PLC. It contains tofacitinib 5 mg, an immunosuppressant. It is used in adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or cannot tolerate methotrexate. It may be taken alone or with methotrexate or other nonbiologic disease-modifying antirheumatic drugs. Tofacitinib works by blocking certain immune signals involved in joint inflammation. Because it affects the immune system, it needs medical supervision. Ask your doctor or pharmacist about anything you are unsure of.
Uses of Jakrif-5
Jakrif-5 is used for adults with moderately to severely active rheumatoid arthritis after methotrexate has not worked well enough or has caused intolerance. It can be used on its own or together with methotrexate or other nonbiologic disease-modifying antirheumatic drugs. It is not a painkiller for everyday aches. Tell your doctor about all your health conditions and other medicines.
How to use Jakrif-5
Take Jakrif-5 exactly as your doctor tells you. The dose and course are decided by your doctor based on your condition and other medicines you take. Swallow the tablet as instructed. Do not change the dose or stop treatment on your own. If you miss a dose, ask your doctor or pharmacist what to do. Keep all appointments for check-ups and tests your doctor advises.
Side effects of Jakrif-5
In clinical trials during the first three months, the most commonly reported side effects were upper respiratory tract infections, headache, diarrhoea and nasopharyngitis. Some people may have other effects. Because tofacitinib affects the immune system, serious infections can occur. Tell your doctor promptly if you notice signs of infection, such as fever, or any unusual symptom. Ask your doctor or pharmacist about what to watch for.
Safety and precautions
Jakrif-5 should not be used during an active serious infection, including localised infections. It is used with caution in people who may be at increased risk of gastrointestinal perforation. Your doctor may arrange laboratory monitoring because of possible changes in blood cells, liver enzymes and lipids. Live vaccines should be avoided with this medicine. Do not start it if certain blood counts are low; your doctor will check. It is pregnancy category C: use in pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether tofacitinib passes into human milk, so breastfeeding decisions need medical advice. Tell your doctor about pregnancy, breastfeeding, infections or other medicines before starting.
Frequently asked questions
What does the generic name tofacitinib mean?
Tofacitinib is the generic name of the active ingredient. It belongs to a group of medicines called janus kinase (JAK) inhibitors. These medicines work by blocking certain immune signals in the body. Jakrif-5 is the brand name of this tofacitinib tablet.
What is Jakrif-5 used for and what kind of medicine is it?
Jakrif-5 is an immunosuppressant tablet. It is used for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate or cannot tolerate it. It may be used alone or with methotrexate or other nonbiologic disease-modifying antirheumatic drugs.
How should Jakrif-5 be taken?
Your doctor decides the dose and how long you take Jakrif-5. Follow their instructions exactly and do not change the dose yourself. If you miss a dose or have questions about taking it, ask your doctor or pharmacist. Keep any appointments for monitoring that your doctor advises.
What should I tell my doctor before starting Jakrif-5?
Tell your doctor about any current or past infections, pregnancy or breastfeeding, liver or kidney problems, and all other medicines you take. Your doctor will assess whether Jakrif-5 is suitable for you and may arrange blood tests. Do not start it during an active serious infection.
Indications
Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Pharmacology
Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve efficacy via other pathways as well.
Dosage & Administration
Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.
Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.
Interaction
- Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)
- Recommended dose is Tofacitinib 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)
- Recommended dose is Tofacitinib 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.
Side Effects
Pregnancy & Lactation
It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother
Precautions & Warnings
- Serious Infections: Avoid use of Tofacitinib during an active serious infection, including localized infections.
- Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
- Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
- Immunizations: Live vaccines: Avoid use with Tofacitinib.
- Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.
Storage Conditions
Alternative brands of Tofacitinib
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.